Massachusetts Cannabis Regulation: Laws, Licensing & Compliance Guide

Executive Summary

Massachusetts cannabis regulation has entered a new phase of controversy as former Cannabis Control Commission Executive Director Shannon O'Brien filed her second lawsuit alleging corruption and retaliation within the state's $1.6 billion marijuana industry. O'Brien, who was removed from her position twice—first in 2023 and again after a brief reinstatement—claims she was ousted for identifying serious regulatory violations, public safety risks, and conflicts of interest within the commission charged with overseeing the state's adult-use and medical marijuana programs. The lawsuit, filed in August 2026, alleges that political interference and industry influence have compromised the integrity of Massachusetts cannabis oversight at a time when the market generates hundreds of millions in annual tax revenue and serves hundreds of thousands of registered patients and adult consumers. The case highlights ongoing tensions between regulatory independence, political accountability, and industry interests in one of the nation's most established state cannabis markets, with implications for how Massachusetts will enforce compliance, protect consumers, and maintain public trust in its regulatory framework as the industry continues to expand.

Why This Matters

The integrity of Massachusetts cannabis regulation directly affects public safety, market fairness, and the legitimacy of a $1.6 billion industry serving more than 6.9 million state residents. Massachusetts operates one of the largest state-regulated cannabis markets in the United States, with over 400 licensed retail locations and cultivation facilities generating approximately $1.4 billion in annual sales as of 2025. The state collected $172 million in cannabis tax revenue in fiscal year 2025, funds earmarked for public health programs, municipal support, and social equity initiatives. For the approximately 75,000 registered medical marijuana patients in Massachusetts, regulatory oversight ensures product safety, accurate labeling, and consistent access to tested medicine. Adult-use consumers, who account for the majority of the market, depend on the Cannabis Control Commission to enforce testing standards for contaminants including pesticides, heavy metals, and microbial impurities. Any compromise in regulatory independence threatens these protections. Licensed operators—from multi-state operators like Curaleaf and Trulieve to small craft cultivators—require consistent, predictable enforcement to compete fairly. Allegations of favoritism or corruption undermine market integrity and disadvantage compliant businesses. The state's social equity program, designed to address the disproportionate impact of cannabis prohibition on communities of color, depends on transparent administration of licensing priorities and technical assistance funding. Investors have committed billions of dollars to Massachusetts cannabis infrastructure based on the assumption of stable, professional regulation. Regulatory uncertainty increases risk premiums and capital costs for operators. For municipalities that have opted into cannabis commerce, local tax revenue and economic development depend on a well-functioning state oversight system that maintains public confidence and prevents federal intervention.

Background and History: Massachusetts Cannabis Regulation from Ballot to Crisis

Massachusetts cannabis regulation evolved from voter-approved legalization in 2016 through years of implementation challenges, political conflicts, and mounting questions about regulatory independence.

Ballot Question 4 and the 2016 Legalization Vote

On November 8, 2016, Massachusetts voters approved Ballot Question 4 with 53.7% support, legalizing possession and cultivation of cannabis for adults 21 and older. The initiative, officially titled "An Initiative Petition for a Law for the Regulation and Taxation of Marijuana," authorized adults to possess up to one ounce in public and ten ounces at home, cultivate up to six plants per person (twelve per household), and established a framework for licensed commercial cultivation, manufacturing, testing, and retail sales. The measure created a new regulatory body, the Cannabis Control Commission, as an independent agency within the state Treasurer's office. The commission was granted broad authority to develop regulations, issue licenses, conduct inspections, and enforce compliance. The law imposed a 3.75% state excise tax on retail sales, in addition to the standard 6.25% state sales tax, with municipalities authorized to add a local option tax of up to 3%.

Legislative Revisions and Delayed Implementation (2017)

The Massachusetts Legislature substantially revised the voter-approved law through Chapter 55 of the Acts of 2017, signed by Governor Charlie Baker in July 2017. Key changes included increasing the maximum state tax from 3.75% to 10.75% when combined with sales tax, strengthening municipal control by requiring host community agreements, and delaying the retail market launch from January 2018 to July 2018. The legislation also modified the Cannabis Control Commission structure, establishing it as a five-member body appointed by the Governor, Treasurer, and Attorney General. The law required commissioners to have expertise in areas including business regulation, public health, law enforcement, and social justice. The commission was tasked with developing comprehensive regulations by March 2018 covering all aspects of the commercial market.

Commission Formation and Initial Regulations (2018)

The Cannabis Control Commission held its first meeting in September 2017 and began the regulatory development process. The commission released draft regulations in November 2017, followed by public hearings across the state that drew thousands of comments from industry stakeholders, municipalities, public health advocates, and residents. Final regulations, codified at 935 CMR 500.000, were approved in March 2018. The 200-page regulatory framework established licensing categories including marijuana cultivator, craft marijuana cooperative, marijuana product manufacturer, independent testing laboratory, marijuana retailer, and marijuana transporter. The regulations set strict seed-to-sale tracking requirements using a state-mandated system, mandatory testing protocols for potency and contaminants, packaging and labeling standards, security requirements, and social consumption prohibitions. The first retail licenses were issued in June 2018, with the first adult-use dispensaries opening in November 2018 in Leicester and Northampton. Massachusetts became the first state on the East Coast to launch legal adult-use cannabis sales.

Early Market Growth and Regulatory Challenges (2019-2021)

The Massachusetts cannabis market expanded rapidly, reaching $393 million in adult-use sales in 2019, $700 million in 2020, and exceeding $1 billion in 2021. The commission issued hundreds of licenses across all categories, though the pace of licensing drew criticism from applicants who experienced processing delays extending beyond the statutory 90-day review period. The commission faced early challenges including testing laboratory capacity constraints that created bottlenecks for product releases, inconsistent enforcement of host community agreement requirements, and questions about the effectiveness of the social equity program. In 2019, the commission launched investigations into several testing laboratories following reports of inflated THC results, leading to license suspensions and heightened scrutiny of testing protocols. The COVID-19 pandemic in 2020 forced operational adaptations including curbside pickup authorization and temporary relief from certain inventory tracking requirements. The commission designated cannabis businesses as essential, allowing continued operations during statewide restrictions.

Shannon O'Brien's First Appointment (2022-2023)

Shannon O'Brien, a former state treasurer and 2002 gubernatorial candidate, was appointed as Executive Director of the Cannabis Control Commission in March 2022. O'Brien brought decades of public service experience and a mandate to professionalize commission operations, improve licensing efficiency, and strengthen enforcement. During her first tenure, O'Brien initiated several reforms including enhanced compliance auditing procedures, stricter oversight of testing laboratories, and efforts to streamline the social equity application process. She also began reviewing host community agreements for potential conflicts of interest and excessive fees charged to applicants. In November 2023, the commission voted 3-2 to terminate O'Brien's employment, citing management style concerns and conflicts with commissioners. O'Brien immediately challenged the termination, alleging it was retaliatory and politically motivated. She claimed she was removed after identifying regulatory violations and resisting pressure to favor certain applicants.

Legal Battle and Reinstatement (2024-2025)

O'Brien filed her first lawsuit in December 2023 in Suffolk Superior Court, alleging wrongful termination, violation of civil service protections, and interference with her statutory duties. The case drew significant media attention and raised questions about commission governance and independence. In June 2024, a Suffolk Superior Court judge issued a preliminary injunction ordering O'Brien's reinstatement pending full adjudication of her claims. The court found she had demonstrated a likelihood of success on the merits and that her removal may have violated procedural requirements. O'Brien returned to her position in July 2024. Her second tenure lasted approximately nine months. During this period, O'Brien reportedly intensified enforcement actions, initiated investigations into several licensed operators, and sought to implement stricter oversight of commission procurement and contracting processes.

Second Removal and August 2026 Lawsuit

In April 2026, the Cannabis Control Commission again voted to remove O'Brien, this time by a 4-1 margin. The commission cited "irreconcilable differences" and "inability to work collaboratively with commissioners" as grounds for termination. O'Brien was placed on administrative leave and formally separated from employment in May 2026. On August 24, 2026, O'Brien filed her second lawsuit, this time making more specific allegations of corruption, conflicts of interest, and public safety risks within the commission and the regulated industry. The complaint alleges she identified serious violations including unlicensed operations, contaminated products reaching consumers, and improper relationships between commissioners and industry participants. O'Brien claims she was removed specifically to prevent disclosure of these issues and to protect politically connected operators from enforcement action.

Key Players in the Massachusetts Cannabis Regulatory Dispute

Shannon O'Brien

Shannon O'Brien served as Massachusetts State Treasurer from 1999 to 2003 and ran as the Democratic nominee for Governor in 2002. She brings extensive experience in state financial management and regulatory oversight. O'Brien was appointed Cannabis Control Commission Executive Director in March 2022 with a mandate to strengthen enforcement and improve operational efficiency. Her tenure has been marked by aggressive enforcement initiatives and conflicts with commissioners over regulatory priorities and commission governance. O'Brien's two lawsuits allege she was removed for identifying corruption and resisting political interference in regulatory decisions.

Cannabis Control Commission

The Cannabis Control Commission is the independent state agency responsible for implementing and enforcing Massachusetts cannabis laws. Established by the 2016 voter initiative and modified by subsequent legislation, the commission consists of five members appointed to staggered terms. The commission has authority to issue licenses, develop regulations, conduct inspections, impose penalties, and revoke licenses. Since 2023, the commission has experienced significant internal conflict, with public disagreements among commissioners and high-profile disputes with executive leadership. The commission oversees approximately 400 active licenses and a market generating over $1.4 billion in annual sales.

Massachusetts Legislature

The Massachusetts General Court has maintained active oversight of cannabis regulation since legalization, holding multiple hearings on commission operations, licensing delays, and social equity program effectiveness. Legislative committees including the Joint Committee on Cannabis Policy and the Joint Committee on Marijuana Policy have investigated commission governance and considered bills to modify regulatory structure. Some legislators have called for commission restructuring or increased legislative oversight in response to the O'Brien disputes and broader concerns about regulatory consistency.

Governor's Office

The Governor appoints three of the five Cannabis Control Commission members and has significant influence over commission direction. Governor Maura Healey, who took office in January 2023, inherited the commission conflicts and has faced pressure to intervene. The Governor's office has generally maintained that the commission operates independently and that personnel matters are within commission authority, though the administration has expressed concern about regulatory stability and public confidence.

Licensed Operators and Industry Associations

Massachusetts cannabis operators include multi-state operators like Curaleaf, Trulieve, and Verano, regional chains, and independent single-location businesses. Industry trade groups including the Commonwealth Dispensary Association and the Massachusetts Cannabis Association for Delivery have engaged in the regulatory debate, with some operators expressing concern about enforcement inconsistency and others supporting stronger oversight. The O'Brien lawsuits have created uncertainty about enforcement priorities and the durability of existing compliance interpretations.

Legal and Regulatory Framework

Massachusetts cannabis regulation operates under a complex legal framework combining voter-approved statutes, legislative amendments, administrative regulations, and ongoing judicial interpretation. The foundational law is Chapter 334 of the Acts of 2016, as amended by Chapter 55 of the Acts of 2017, codified at Massachusetts General Laws Chapter 94G. This statute establishes the Cannabis Control Commission, defines its powers and duties, sets licensing categories, and creates the basic tax structure. Section 4 of Chapter 94G grants the commission broad rulemaking authority to "adopt regulations to implement" the law and "ensure the safe cultivation, manufacture, and sale of marijuana." The commission's regulations at 935 CMR 500.000 provide detailed requirements for all license types. Key regulatory provisions include mandatory testing for potency, pesticides, heavy metals, mycotoxins, and microbial contaminants; seed-to-sale tracking using the state's contracted system; packaging requirements including child-resistant containers and warning labels; security standards including video surveillance and alarm systems; and restrictions on advertising and marketing. Massachusetts cannabis law intersects with federal law in significant ways. Cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act, 21 U.S.C. § 812, creating ongoing legal uncertainty despite state legalization. The Rohrabacher-Farr Amendment and subsequent appropriations riders have limited federal enforcement against state-compliant medical marijuana programs, but adult-use operations remain theoretically subject to federal prosecution. The 2018 Farm Bill, 7 U.S.C. § 1639o, legalized hemp with less than 0.3% delta-9 THC, creating regulatory complexity around hemp-derived cannabinoids. State employment law protections for cannabis use remain limited. While Massachusetts General Laws Chapter 94C, Section 34 prohibits employment discrimination against medical marijuana patients, courts have held that employers may enforce drug-free workplace policies. The Massachusetts Supreme Judicial Court's 2017 decision in Barbuto v. Advantage Sales and Marketing established that employers must engage in an interactive process to determine reasonable accommodations for medical marijuana patients, but employers may still prohibit use that impairs job performance or violates federal requirements. Tax law creates significant compliance burdens. Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses, forcing cannabis operators to pay federal income tax on gross profit rather than net income. This creates effective federal tax rates often exceeding 70% for retail operators. Massachusetts state tax law does not incorporate Section 280E, allowing normal business deductions for state tax purposes.

State-by-State Context: Massachusetts in the Regional Cannabis Market

Massachusetts operates within a competitive Northeast regional cannabis market with varying regulatory approaches in neighboring states.

Massachusetts

Adult-use legal since 2016 ballot measure; sales began November 2018. Possession limit: one ounce in public, ten ounces at home. Home cultivation: six plants per person, twelve per household. Licensing: comprehensive regulatory system with multiple license types. Tax structure: 10.75% state excise and sales tax, plus up to 3% local option tax. Market size: approximately $1.4 billion in annual sales as of 2025. Social equity program includes licensing priority, technical assistance, and fee waivers for qualifying applicants from communities disproportionately impacted by prohibition.

Maine

Adult-use legal since 2016 ballot measure; sales began October 2020. Possession limit: 2.5 ounces. Home cultivation: three mature plants, twelve immature plants per person. Licensing: separate medical and adult-use regulatory systems. Tax structure: 10% state excise tax, plus 3% local option tax. Market size: approximately $350 million annually. Maine's later market launch and smaller population have limited competitive pressure on Massachusetts operators.

Vermont

Adult-use possession and home cultivation legal since 2018; retail sales began October 2022. Possession limit: one ounce in public, two ounces at home. Home cultivation: two mature plants, four immature plants per person. Licensing: Cannabis Control Board regulates retail market. Tax structure: 14% excise tax. Market size: approximately $75 million annually in early stages. Vermont's small market and limited retail infrastructure create minimal competition for Massachusetts.

Connecticut

Adult-use legal since 2021; sales began January 2023. Possession limit: 1.5 ounces in public, five ounces at home. Home cultivation: prohibited until July 2023, then six plants per person, twelve per household. Licensing: Department of Consumer Protection regulates market. Tax structure: 6.35% sales tax plus excise tax based on THC content. Market size: approximately $300 million annually. Connecticut's market launch reduced some Massachusetts border sales but geographic coverage remains limited.

Rhode Island

Adult-use legal since 2022; sales began December 2022. Possession limit: one ounce in public, ten ounces at home. Home cultivation: six plants per person, twelve per household. Licensing: Cannabis Control Commission regulates market. Tax structure: 10% cannabis excise tax, 7% sales tax, plus 3% local tax. Market size: approximately $150 million annually. Rhode Island's small size limits market impact but provides convenient access for southeastern Massachusetts residents.

New York

Adult-use legal since 2021; limited retail sales began December 2022 with significant delays. Possession limit: three ounces. Home cultivation: prohibited. Licensing: Office of Cannabis Management regulates market. Tax structure: 13% excise tax plus per-milligram THC tax. Market size: projected to reach $1 billion but implementation challenges have delayed market development. New York's regulatory struggles have benefited Massachusetts operators serving western Massachusetts and the Albany region.

New Hampshire

No legal adult-use market; medical marijuana only. New Hampshire's prohibition creates significant cross-border demand, with Massachusetts border communities seeing substantial out-of-state customer traffic. New Hampshire legislative efforts to legalize adult-use sales have repeatedly failed, maintaining Massachusetts' competitive advantage.

Market and Business Implications

Regulatory instability and allegations of corruption create significant business uncertainty for Massachusetts cannabis operators, investors, and ancillary service providers. The Massachusetts cannabis market generated approximately $1.43 billion in total sales in 2025, with adult-use sales accounting for roughly $1.28 billion and medical sales contributing $150 million. The market supports over 400 active licenses across cultivation, manufacturing, testing, transportation, and retail categories. Industry employment exceeds 15,000 direct jobs, with thousands more in ancillary services including legal, accounting, security, construction, and equipment supply. Multi-state operators have made substantial capital investments in Massachusetts infrastructure. Curaleaf operates over 20 retail locations in the state and maintains significant cultivation and manufacturing capacity. Trulieve, Verano, and other MSOs have invested tens of millions in acquisitions and facility development. Regulatory uncertainty affects these operators' ability to forecast revenue, plan expansion, and secure financing for growth. The O'Brien lawsuits and commission conflicts create specific business risks. Allegations of inconsistent enforcement raise questions about whether all operators face equal compliance scrutiny. Claims of corruption and favoritism undermine confidence in licensing decisions, potentially exposing approved licenses to legal challenge. Operators who invested based on specific regulatory interpretations face uncertainty about whether those interpretations will remain stable. Testing laboratory operations face particular scrutiny. Massachusetts requires all cannabis products to undergo testing by independent, commission-licensed laboratories for potency, pesticides, heavy metals, mycotoxins, and microbial contaminants. The commission has suspended or revoked multiple laboratory licenses for testing irregularities, creating capacity constraints and raising questions about result reliability. O'Brien's allegations of contaminated products reaching consumers, if substantiated, could trigger product recalls, liability claims, and consumer confidence damage. Wholesale pricing has shown volatility correlated with regulatory uncertainty. Massachusetts wholesale flower prices averaged approximately $2,800 per pound in mid-2026, down from over $3,500 in 2024, reflecting increased cultivation capacity and competitive pressure. Regulatory instability adds risk premium to pricing and makes long-term supply agreements more difficult to negotiate. Capital markets remain challenging for cannabis operators due to federal prohibition and banking restrictions. The failure of the SAFE Banking Act to pass Congress has left Massachusetts operators dependent on limited state-chartered banks willing to serve the industry and expensive private capital. Regulatory controversy in a major market like Massachusetts increases investor risk perception and raises capital costs across the sector. Social equity applicants face particular vulnerability. The commission's social equity program provides licensing priority, technical assistance, and fee waivers for applicants from communities disproportionately harmed by cannabis prohibition. Program effectiveness depends on consistent administration and adequate funding. Commission instability and leadership turnover disrupt technical assistance delivery and create uncertainty about program priorities. Social equity licensees, often undercapitalized compared to established operators, have less capacity to absorb regulatory uncertainty. Municipal revenue depends on stable cannabis commerce. Communities that have opted into cannabis businesses through local approval processes and host community agreements rely on local option taxes and host community fees for budget planning. In fiscal year 2025, Massachusetts municipalities collected approximately $45 million in local cannabis taxes. Regulatory controversy that reduces consumer confidence or triggers federal intervention threatens this revenue stream.

What Experts and Stakeholders Say

Cannabis industry stakeholders, legal experts, and policy advocates have expressed divergent views on the Massachusetts regulatory crisis and its implications. According to the Commonwealth Dispensary Association, the state's largest cannabis trade group, regulatory consistency and predictable enforcement are essential for business planning and investment. The association has called for commission reforms to ensure professional management and reduce political interference in regulatory decisions. Industry representatives have emphasized that operators need clear rules applied uniformly across all license holders. Legal experts specializing in cannabis law have noted that the O'Brien disputes highlight broader tensions in cannabis regulation between political accountability and regulatory independence. Attorneys representing cannabis clients have observed that commission instability creates compliance uncertainty and makes it difficult to advise clients on regulatory risk. Some legal commentators have suggested that Massachusetts should consider structural reforms similar to those in other states, such as placing the regulatory agency within an existing executive department rather than maintaining it as an independent commission. Public health advocates have expressed concern that regulatory dysfunction could compromise product safety oversight. Organizations focused on cannabis harm reduction have emphasized the importance of rigorous testing standards and consistent enforcement to protect consumers, particularly medical marijuana patients who may be immunocompromised or otherwise vulnerable to contaminants. Public health experts have noted that any erosion of testing integrity or enforcement could undermine the public health rationale for regulated legalization. Social equity advocates have warned that commission instability disproportionately harms equity applicants who lack the resources and political connections of established operators. Organizations working with equity applicants have reported that leadership turnover and program uncertainty have delayed technical assistance delivery and made it harder for equity businesses to access capital and navigate the licensing process. Advocates have called for dedicated funding and structural protections to insulate the equity program from political interference. Municipal officials in communities that have approved cannabis businesses have expressed frustration with state-level regulatory uncertainty. Local officials have noted that they rely on state oversight to ensure operators comply with security, testing, and operational standards, and that commission dysfunction undermines the local regulatory partnership. Some municipalities have considered pausing new cannabis approvals until state regulatory stability is restored. Reform advocates who supported the 2016 legalization ballot measure have expressed disappointment that implementation has been marked by political conflict rather than professional regulation. Legalization supporters have argued that the voter-approved framework intended to create independent, expert regulation insulated from political pressure, and that the O'Brien disputes suggest this goal has not been achieved. Some advocates have called for renewed citizen oversight and transparency measures.

What's Next: Key Dates and Decision Points

The Massachusetts cannabis regulatory landscape faces several critical decision points in the coming months that will shape the industry's future stability and integrity. The O'Brien lawsuit filed in August 2026 will proceed through Suffolk Superior Court with several key milestones. The Cannabis Control Commission is expected to file a motion to dismiss by October 2026, arguing that O'Brien's claims are barred by prior litigation or fail to state valid legal claims. O'Brien's legal team will oppose dismissal and seek discovery of commission documents and communications. If the case survives dismissal, discovery could extend through early 2027, potentially revealing internal commission deliberations and enforcement decisions. A trial, if reached, would likely occur in late 2027 or 2028. The commission must appoint a new executive director or interim leadership. As of August 2026, the commission has not announced a permanent replacement for O'Brien. The selection process and the new leader's priorities will significantly impact enforcement direction and industry relations. A reform-oriented appointee could validate O'Brien's concerns and intensify enforcement, while a more industry-friendly leader might signal a shift toward cooperative regulation. The Massachusetts Legislature's Joint Committee on Cannabis Policy has scheduled oversight hearings for fall 2026 to examine commission governance and the allegations raised in O'Brien's lawsuit. These hearings could lead to legislative proposals to restructure the commission, modify appointment processes, or increase legislative oversight. Any structural reforms would require passage by both chambers and the Governor's signature, a process unlikely to conclude before mid-2027. Several enforcement actions reportedly initiated by O'Brien during her tenure remain pending. The commission must decide whether to pursue these investigations or close them. These decisions will signal enforcement priorities and could validate or refute O'Brien's claims about regulatory capture. Industry observers expect the commission to announce enforcement actions or case closures by late 2026. The commission faces a March 2027 deadline to submit its annual report to the Legislature detailing market activity, enforcement actions, and program effectiveness. This report will provide the first comprehensive public accounting of commission operations during the period of O'Brien's allegations. The report's candor and completeness will affect legislative and public confidence. Federal cannabis policy developments could impact Massachusetts regulation. The Drug Enforcement Administration's ongoing review of cannabis scheduling, initiated in 2023, could result in rescheduling cannabis to Schedule III or lower, which would eliminate Internal Revenue Code Section 280E tax penalties and reduce federal-state legal conflicts. Any federal rescheduling decision is expected by late 2026 or early 2027. Additionally, renewed congressional consideration of the SAFE Banking Act or comprehensive cannabis reform could provide legal clarity that reduces state regulatory pressure. Social equity program reforms are under consideration. Advocacy groups have proposed dedicated funding, structural independence for equity program administration, and enhanced accountability measures. The commission is expected to consider equity program modifications in late 2026, though significant changes may require legislative action.

Further Reading and Primary Sources

• Massachusetts General Laws Chapter 94G: Regulation of the Use and Distribution of Marijuana Not Medically Prescribed - https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXV/Chapter94G
• Cannabis Control Commission Regulations, 935 CMR 500.000 - https://mass-cannabis-control.com/regulations/
• Cannabis Control Commission Official Website - https://mass-cannabis-control.com/
• Massachusetts Ballot Question 4 (2016) Full Text - https://www.sec.state.ma.us/ele/ele16/ballot_questions_16/quest4.htm
• Chapter 55 of the Acts of 2017 (Legislative Amendments to Ballot Question 4) - https://malegislature.gov/Laws/SessionLaws/Acts/2017/Chapter55
• Suffolk Superior Court Case Docket: O'Brien v. Cannabis Control Commission - Available through Massachusetts Trial Court Electronic Case Access
• Massachusetts Cannabis Industry Sales Data and Reports - https://mass-cannabis-control.com/open-data/
• Joint Committee on Cannabis Policy - https://malegislature.gov/Committees/Detail/J28
• U.S. Controlled Substances Act, 21 U.S.C. § 812 - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13-subchapI-partB-sec812.pdf
• Internal Revenue Code Section 280E - https://www.law.cornell.edu/uscode/text/26/280E
• Barbuto v. Advantage Sales and Marketing, LLC, 477 Mass. 456 (2017) - https://www.mass.gov/supreme-judicial-court-opinions
• Commonwealth Dispensary Association - https://www.compassionforpatients.com/
• MJBizDaily Massachusetts Cannabis News Coverage - https://mjbizdaily.com/tag/massachusetts/